Gabriel Pardo to Multiple Sclerosis
This is a "connection" page, showing publications Gabriel Pardo has written about Multiple Sclerosis.
Connection Strength
3.044
-
Outcome measures assisting treatment optimization in multiple sclerosis. J Neurol. 2022 Mar; 269(3):1282-1297.
Score: 0.710
-
Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. J Manag Care Spec Pharm. 2021 May; 27(5):639-649.
Score: 0.689
-
Reduced retinal nerve fiber layer and macular thickness in patients with multiple sclerosis with no history of optic neuritis identified by the use of spectral domain high-definition optical coherence tomography. J Clin Neurosci. 2011 Nov; 18(11):1469-72.
Score: 0.358
-
Arterial compliance in multiple sclerosis: a pilot study. Angiology. 2010 Feb-Mar; 61(1):31-6.
Score: 0.305
-
Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL. Mult Scler Relat Disord. 2022 Jul; 63:103922.
Score: 0.188
-
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102454.
Score: 0.166
-
Relationship between soleus H-reflex asymmetry and postural control in multiple sclerosis. Disabil Rehabil. 2022 Feb; 44(4):542-548.
Score: 0.164
-
Evaluation of Power Production Asymmetry during Cycling in Persons with Multiple Sclerosis. Int J Environ Res Public Health. 2019 09 17; 16(18).
Score: 0.156
-
Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. J Autoimmun. 2020 01; 106:102332.
Score: 0.156
-
Decreased postural balance in multiple sclerosis patients with low disability. Int J Rehabil Res. 2011 Mar; 34(1):53-8.
Score: 0.086
-
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther. 2007 Jun; 29(6):1128-45.
Score: 0.066